Brian J. Davis, M.D., Ph.D.

Closed for Enrollment

• A Multi-Center Trial Of Androgen Suppression With Abiraterone ACetate, LEuprolide, PARP Inhibition And Stereotactic Body Radiotherapy (ASCLEPIuS): A Phase I/2 Trial In High Risk And Node Positive Prostate Cancer Rochester, MN

  The purpose of this study is to establish the maximum tolerable dose of niraparib when combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone (phase 1 portion of the study) and determine 3-year biochemical PSA recurrence free-survival with this treatment approach (phase 2 portion of the study).

• A Randomized, Parallel Phase II Trial Of Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer Involving Only Pelvic And/or Para-aortic Lymph Nodes Following Primary Localized Treatment Rochester, MN

  The purpose of this study is to assess late > grade 3 GI and/or GU toxicity of interest with the hypofractionated regimen with proton beam therapy or IMRT (late defined as 3 to 24 months after protocol RT).